Ibtissam Acem1, Cornelis Verhoef2, Anja J Rueten-Budde3, Dirk J Grünhagen2, Winan J van Houdt4, Michiel A J van de Sande5. 1. Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands; The Netherlands Department of Orthopedic Surgery, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands. Electronic address: i.acem@lumc.nl. 2. Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands. 3. Mathematical Institute, Leiden University, Niels Bohrweg 1, 2333 CA, Leiden, the Netherlands. 4. Department of Surgical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. 5. The Netherlands Department of Orthopedic Surgery, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
Abstract
PURPOSE: No studies extensively compared the young adults (YA, 18-39 years), middle-aged (40-69 years), and elderly (≥70 years) population with primary high-grade extremity soft tissue sarcoma (eSTS). This study aimed to determine whether the known effect of age on overall survival (OS) and disease progression can be explained by differences in tumour characteristics and treatment protocol among the YA, middle-aged and elderly population in patients with primary high-grade eSTS treated with curative intent. METHODS: In this retrospective multicentre study, inclusion criteria were patients with primary high-grade eSTS of 18 years and older, surgically treated with curative intent between 2000 and 2016. Cox proportional hazard models and a multistate model were used to determine the association of age on OS and disease progression. RESULTS: A total of 6260 patients were included in this study. YA presented more often after 'whoops'-surgery or for reresection due to residual disease, and with more deep-seated tumours. Elderly patients presented more often with grade III and larger (≥10 cm) tumours. After adjustment for the imbalance in tumour and treatment characteristics the hazard ratio for OS of the middle-aged population is 1.47 (95% confidence interval [CI]: 1.23-1.76) and 3.13 (95% CI: 2.59-3.78) in the elderly population, compared with YA. DISCUSSION: The effect of age on OS could only partially be explained by the imbalance in the tumour characteristics and treatment variables. The threefold higher risk of elderly could, at least partially, be explained by a higher other-cause mortality. The results might also be explained by a different tumour behaviour or suboptimal treatment in elderly compared with the younger population.
PURPOSE: No studies extensively compared the young adults (YA, 18-39 years), middle-aged (40-69 years), and elderly (≥70 years) population with primary high-grade extremity soft tissue sarcoma (eSTS). This study aimed to determine whether the known effect of age on overall survival (OS) and disease progression can be explained by differences in tumour characteristics and treatment protocol among the YA, middle-aged and elderly population in patients with primary high-grade eSTS treated with curative intent. METHODS: In this retrospective multicentre study, inclusion criteria were patients with primary high-grade eSTS of 18 years and older, surgically treated with curative intent between 2000 and 2016. Cox proportional hazard models and a multistate model were used to determine the association of age on OS and disease progression. RESULTS: A total of 6260 patients were included in this study. YA presented more often after 'whoops'-surgery or for reresection due to residual disease, and with more deep-seated tumours. Elderly patients presented more often with grade III and larger (≥10 cm) tumours. After adjustment for the imbalance in tumour and treatment characteristics the hazard ratio for OS of the middle-aged population is 1.47 (95% confidence interval [CI]: 1.23-1.76) and 3.13 (95% CI: 2.59-3.78) in the elderly population, compared with YA. DISCUSSION: The effect of age on OS could only partially be explained by the imbalance in the tumour characteristics and treatment variables. The threefold higher risk of elderly could, at least partially, be explained by a higher other-cause mortality. The results might also be explained by a different tumour behaviour or suboptimal treatment in elderly compared with the younger population.
Authors: Fabio Tirotta; Michael G Fadel; James Hodson; Alessandro Parente; Helene Wilkerson; L Max Almond; Samuel J Ford; Andrew J Hayes; Anant Desai; Dirk C Strauss Journal: Ann Surg Oncol Date: 2022-07-19 Impact factor: 4.339
Authors: Gijsbert M Kalisvaart; Willem Grootjans; Judith V M G Bovée; Hans Gelderblom; Jos A van der Hage; Michiel A J van de Sande; Floris H P van Velden; Johan L Bloem; Lioe-Fee de Geus-Oei Journal: Diagnostics (Basel) Date: 2021-12-04
Authors: Ibtissam Acem; Merel M Smit; Cornelis Verhoef; Winan J van Houdt; Rick L Haas; Jos A van der Hage; Dirk J Grünhagen; Michiel A J van de Sande Journal: Ann Surg Oncol Date: 2021-05-10 Impact factor: 5.344
Authors: Andrea Sambri; Emilia Caldari; Andrea Montanari; Michele Fiore; Luca Cevolani; Federico Ponti; Valerio D'Agostino; Giuseppe Bianchi; Marco Miceli; Paolo Spinnato; Massimiliano De Paolis; Davide Maria Donati Journal: Cancers (Basel) Date: 2021-12-16 Impact factor: 6.639
Authors: Annika Frei; Mario F Scaglioni; Pietro Giovanoli; Stefan Breitenstein; Philip Heesen; Bruno Fuchs Journal: Cancers (Basel) Date: 2022-03-18 Impact factor: 6.639